Verve Therapeutics Price to Free Cash Flow Ratio 2020-2024 | VERV

Verve Therapeutics price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as

Verve Therapeutics Price to Free Cash Flow Ratio 2020-2024 | VERV

Verve Therapeutics price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$89B
Takeda Pharmaceutical (TAK)$47.2B
Merck (MKGAF)$23.7B
Astellas Pharma (ALPMY)$22.1B
Summit Therapeutics (SMMT)$17.8B
Sandoz Group AG (SDZNY)$17.6B
United Therapeutics (UTHR)$15.2B
Shionogi (SGIOY)$13.1B
Neurocrine Biosciences (NBIX)$12.1B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$6.2B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.1B
Corcept Therapeutics (CORT)$4.4B
Crinetics Pharmaceuticals (CRNX)$4.2B
Dyne Therapeutics (DYN)$3.4B
PTC Therapeutics (PTCT)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Harrow (HROW)$1.6B
Cassava Sciences (SAVA)$1.5B